| PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity JE Saavedra, A Srinivasan, GS Buzard, KM Davies, DJ Waterhouse, ... Journal of medicinal chemistry 49 (3), 1157-1164, 2006 | 103 | 2006 |
| Single ocular injection of a sustained-release anti-VEGF delivers 6 months pharmacokinetics and efficacy in a primate laser CNV model P Adamson, T Wilde, E Dobrzynski, C Sychterz, R Polsky, E Kurali, ... Journal of Controlled Release 244, 1-13, 2016 | 59 | 2016 |
| Hydrolytic Reactivity Trends among Potential Prodrugs of the O2-Glycosylated Diazeniumdiolate Family. Targeting Nitric Oxide to Macrophages for Antileishmanial … CA Valdez, JE Saavedra, BM Showalter, KM Davies, TC Wilde, ML Citro, ... Journal of medicinal chemistry 51 (13), 3961-3970, 2008 | 41 | 2008 |
| Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound H Chakrapani, TC Wilde, ML Citro, MM Goodblatt, LK Keefer, ... Bioorganic & medicinal chemistry 16 (5), 2657-2664, 2008 | 38 | 2008 |
| Experimental evidence for enzyme-enhanced coupled motion/quantum mechanical hydrogen tunneling by ketosteroid isomerase TC Wilde, G Blotny, RM Pollack Journal of the American Chemical Society 130 (20), 6577-6585, 2008 | 29 | 2008 |
| Discovery of a GPR40 superagonist: the impact of aryl propionic acid α-fluorination H Huang, SK Meegalla, JC Lanter, MP Winters, S Zhao, J Littrell, J Qi, ... ACS Medicinal Chemistry Letters 10 (1), 16-21, 2018 | 19 | 2018 |
| Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534 X Xue, A De Leon-Tabaldo, R Luna-Roman, G Castro, M Albers, ... Scientific Reports 11 (1), 11066, 2021 | 18 | 2021 |
| Gut-restricted selective cyclooxygenase-2 (COX-2) inhibitors for chemoprevention of colorectal cancer Z Zhang, A Ghosh, PJ Connolly, P King, T Wilde, J Wang, Y Dong, X Li, ... Journal of Medicinal Chemistry 64 (15), 11570-11596, 2021 | 16 | 2021 |
| Selective Catalysis of Elementary Steps by Asp-99 and Tyr-14 of 3-Oxo-Δ5-Steroid Isomerase LD Thornburg, YR Goldfeder, TC Wilde, RM Pollack Journal of the American Chemical Society 123 (40), 9912-9913, 2001 | 16 | 2001 |
| Abstract 5567A: JNJ-‘6196: A next generation STING agonist with potent preclinical activity by the IV route SR Chan, G Bignan, E Pierson, S Mahady, H Ta, W Schepens, ... Cancer Research 80 (16_Supplement), 5567A-5567A, 2020 | 4 | 2020 |
| Minimal physiologically-based pharmacokinetic (mPBPK) metamodeling of target engagement in skin informs anti-il17a drug development in psoriasis VS Ayyar, JB Lee, W Wang, M Pryor, Y Zhuang, T Wilde, A Vermeulen Frontiers in Pharmacology 13, 862291, 2022 | 2 | 2022 |
| Six months effective ocular drug levels and protection against laser CNV in a cynomolgus monkey after a single ocular administration of a biodegradable microsphere delivery … IR Catchpole, P Adamson, T Wilde, E Dobrzynski, C Sychertz, R Polsky, ... Investigative Ophthalmology & Visual Science 56 (7), 1498-1498, 2015 | 2 | 2015 |
| In silico mechanistic model for understanding intravitreal dosing frequency of anti-VEGF therapies T Wilde, V Damian Investigative Ophthalmology & Visual Science 55 (13), 601-601, 2014 | 2 | 2014 |
| Disposition and metabolism of [14C] dabrafenib, a RAF kinase inhibitor, in mice, rats, dogs and humans LE Richards-Peterson, TC Wilde, DB Mamaril-Fishman, DA Bershas, ... DRUG METABOLISM REVIEWS 45, 190-191, 2014 | 2 | 2014 |
| Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534 X Xue, A De Leon-Tabaldo, R Luna-Roman, G Castro, M Albers, ... Scientific Reports 12 (1), 5740, 2022 | 1 | 2022 |
| Development of a plasma/dermis population pharmacokinetic model for GSK1940029 J Zhu, T Wilde, R Brigandi J Pharmacokinet Pharmacodyn 42, S99, 2015 | 1 | 2015 |
| A Quantitative Systems Pharmacology (QSP) Approach to Understand the Pathogenesis of Acne and to Evaluate New Acne Therapies L Bansal, T Wilde, A Gupta, G Kang, S Frey, B Hussey, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 41, S22-S23, 2014 | 1 | 2014 |
| Improvement Of Corneal Staining By A Sirt1 Activator In A Mouse Model Of Dry Eye AH Krauss, F Amparo, A Okanobo, DC Gale, TC Wilde, C Sychterz, ... Investigative Ophthalmology & Visual Science 53 (14), 2343-2343, 2012 | 1 | 2012 |
| Abstract CT114: Data from first-in-human study of EXS21546, an A2A receptor antagonist, now progressing into phase 1 in RCC/NSCLC N Diaz, H Garratt, A Zemla-Brown, M Dominguez, E Helmer, I Alt, ... Cancer Research 83 (8_Supplement), CT114-CT114, 2023 | | 2023 |
| Combination therapy using a malt1 inhibitor and a btk inhibitor AT Greway, U Philippar, B Verbist, TC Wilde, ME Willemin, YA Elsayed, ... US Patent App. 17/683,470, 2022 | | 2022 |
